• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    • Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Mitochondrially-targeted deferoxamine induces mitophagy and acts as anti-cancer agent in vivo

    Author(s)
    Sandoval-Acuna, C
    Torrealba, N
    Tomkova, V
    Blazkova, K
    Neuzil, J
    Stursa, J
    Werner, L
    Truksa, J
    Griffith University Author(s)
    Neuzil, Jiri
    Year published
    2019
    Metadata
    Show full item record
    Abstract
    Iron is a crucial nutrient for proliferating cancer cells. Thus, we have synthesized a mitochondrially targeted derivative of the iron chelator deferoxamine (mDFO) and evaluated its ability to selectively eliminate cancer cells both in vitro and in vivo. Viability of human cancer cells treated with mDFO was assessed by crystal violet or annexin V staining. ROS production was assessed through fluorescent probes MitoSOX and DCF. Blue native electrophoresis and Seahorse were used to analyse mitochondrial function. The in vivo effect of mDFO was assessed by xenografting triple negative breast cancer cells in NOD/Scid mice. Our ...
    View more >
    Iron is a crucial nutrient for proliferating cancer cells. Thus, we have synthesized a mitochondrially targeted derivative of the iron chelator deferoxamine (mDFO) and evaluated its ability to selectively eliminate cancer cells both in vitro and in vivo. Viability of human cancer cells treated with mDFO was assessed by crystal violet or annexin V staining. ROS production was assessed through fluorescent probes MitoSOX and DCF. Blue native electrophoresis and Seahorse were used to analyse mitochondrial function. The in vivo effect of mDFO was assessed by xenografting triple negative breast cancer cells in NOD/Scid mice. Our results show that mDFO is at least 100-fold more efficient than DFO in killing cancer cells. In addition, mDFO was shown to reduce respiration and dramatically decrease the amount and composition of mitochondrial respiratory supercomplexes. Both the latter effects might trigger the observed increase in mitochondrial superoxide production, the fragmentation of mitochondria and the activation of mitophagy. Importantly, in vivo results show that mDFO is effective in slowing the tumour growth. mDFO represents an effective drug to inhibit tumour growth in vivo and might represent the lead compound in a new generation of anti-cancer agents based on mitochondrial iron chelation.
    View less >
    Conference Title
    Free Radical Biology and Medicine
    Volume
    139
    Issue
    Supplement 1
    DOI
    https://doi.org/10.1016/j.freeradbiomed.2019.05.021
    Subject
    Medicinal and biomolecular chemistry
    Biochemistry and cell biology
    Medical biochemistry and metabolomics
    Science & Technology
    Life Sciences & Biomedicine
    Biochemistry & Molecular Biology
    Endocrinology & Metabolism
    Publication URI
    http://hdl.handle.net/10072/392875
    Collection
    • Conference outputs

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E
    • TEQSA: PRV12076

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander